Clonazolam is a highly potent depressant of the triazolobenzodiazepine class, structurally related to both clonazepam and alprazolam. First synthesized in 1971, it was never marketed pharmaceutically and has been available as a research chemical since the mid-2000s. It is considered to pose higher risks than many other designer benzodiazepines due to its exceptional potency, with strong sedation and amnesia reported at very low doses. Blackouts and dependence are frequently reported concerns.
Klonazolam molecular structure diagram from the DrugsPRO substance library.
Also known as: C-lam, Clonitrazolam
Classification
Chemical: Benzodiazepine
Psychoactive: Depressant
Tag: Anxiolytic
Tag: Common
Tag: GABAergic
Tag: Habit-Forming
Tag: Muscle Relaxant
Tag: Research-Chemical
Tag: Sedative
Tag: Triazolobenzodiazepine
Effects
Sedation
Respiratory Depression
Muscle Relaxation
Anxiolytic
Sedative
Dystaxia
Amnesia
Anxiety Suppression
Thought Deceleration
Information Processing Suppression
Euphoria
Compulsive Redosing
Disinhibition
Dulled Perception
Routes of Administration
Oral
Dosage
Heavy: 500-1000 ug
Light: 50 – 200 µg
Common: 200 – 400 µg
Strong: 400 – 500 µg
Threshold: 50-75 ug
Duration
Onset: 0.17-0.5 h
After Effects: 1-12 h
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Get the full DrugsPRO experience
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
Clonazolam - DrugsPRO sprievodca látky
Clonazolam: Clonazolam is a highly potent depressant of the triazolobenzodiazepine class, structurally related to both clonazepam and alprazolam. First synthesized in 1971, it was never marketed pharmaceutically and has been available as a research chemical since the mid-2000s. It is considered to p